ThermoGenesis has named J. Melville Engle as CEO. He has more than 30 years of management experience in the healthcare industry.
Oliver Fetzer has been named the new CEO of Cerulean Pharma.
Howard Greene, the co-founder and former chief executive of Amylin Pharmaceuticals, has resigned from the board.
Mylan has appointed Andrew G. Cuneo, a former Merrill Lynch investment banker, as vice president of global business development.
Dionex announced the appointment of Frank Witney as its CEO, president and a member of the board.
Raptor Pharmaceuticals has appointed Patrice Rioux as its new chief medical officer.
Halozyme Therapeutics has appointed Kurt Gustafson as vice president of finance.
Acorda Therapeutics has promoted Dr. Anthony Caggiano to vice president of preclinical development.
Cornerstone Therapeutics announced the resignation of Chenyqua Baldwin, vice president, finance, and chief accounting officer.
Auspex Pharmaceuticals has appointed Ronald C. Newbold, Ph.D., as chief business officer; Andreas Sommer, Ph.D., as vice president, operations; and Tadimeti Rao, Ph.D., as vice president, preclinical development.
Signature Genomic Laboratories appointed Trilochan Sahoo, M.D., as a laboratory director.
SeraCare Life Sciences has appointed Harold S. Blue to the company's board of directors.
EpiCept has appointed Collier Smyth, former senior vice president of medical strategy - oncology at Bristol-Myers Squibb Company, to its board of directors.
TcLand Expression has named Patrick F. Terry as a new member of its board of directors.
ImmuneRegen BioSciences announced that Adriana T. Larregina, M.D., Ph.D., and Jacob Finkelstein, Ph.D. have accepted invitations to join the company's scientific advisory board.
Zymeworks announced the appointment of Dr. Paul J. Carter, the CSO of VLST, to its scientific advisory board.
Febit has recruited Paul Keim, Ph.D., for its scientific advisory board.
Gene Network Sciences has named Dr. Eric Schadt co-chair of its scientific advisory board.